Kerala HC directs Health Ministry, DoP to reply on unaffordability of patented cancer drug Ribociclib
|
Overview
The Kerala High Court has directed the Department of Pharmaceuticals (DoP) and a competent officer of Union Health Ministry to file their reply on the issue of unaffordability of a life-saving patented breast cancer drug, Ribociclib, within one month.
The case concerned a petitioner diagnosed with HER2- Negative Metastatic Breast Cancer who was undergoing 'targeted therapy' treatment. The monthly cost of the medicines for treatment worked out to Rs. 63,480/. However, the petitioner was receiving a monthly pension of Rs. 28000/ only, and, eventually succumbed to her illness.
For more details, check out the link given below:
Speakers
Roshni Dhar, a Mass com graduate with a soft corner for health happenings, joined Medical Dialogues as a news anchor in 2021. Inspired by her mother who is a gynaecologist, she likes to keep herself and the world updated on the occurring in the medical field. She covers various aspects of health news for MDTV at Medical Dialogues. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751
